摘要
在世界范围内，抗抑郁药(AD)和磷酸二酯酶-5抑制剂(PDE-5I)是治疗共病理性心理健康问题和性功能障碍(SD)患者的常用精神药理学药物。5-羟色胺和去甲肾上腺素能ADS虽然有效，但并非没有任何SD不良反应，特别是勃起功能障碍(ED)。ED是指在男性性兴奋阶段未能获得令人满意的勃起来奖励性交。这被认为是在AD患者中观察到不坚持治疗的一个重要原因。AD干预可缓解部分ED治疗前的精神病理改变。然而，在许多患者中，AD潜在地放大了不必要的性副作用。这给心理健康专业人员带来了挑战。这些挑战是基于ED的复杂性，其病因和相关的危险因素，这进一步增加了AD的副作用。讨论了AD治疗选择的神经-精神药理学基础。建议在两个关键阶段进行生物心理社会干预。首先，应采取步骤进行适当的评估(例如详细的病史、心理社会和实验室调查)，并确定很少有可改变的风险因素导致ED和相关的心理健康问题。其次，在算法路径的指导下，实际的干预应该包括减少剂量、增强或改变对性副作用较小或无影响的AD等策略。建议在患者发生不良性反应时使用5-羟色胺选择性再摄取抑制剂(SSRI)、5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)和三环抗抑郁药(TCA)。很少有可能被记住的建议是修改性脚本，改进性技术，改变生活方式，心理治疗和其他可能对患者和他们的伴侣都有利的非药理学方法。
关键词: 抗抑郁药、磷酸二酯酶类型5抑制剂（PDE-5）、勃起功能障碍（ED）。
图形摘要
[1]
Saba Moussavi SC. Emese Verdes, Ajay Tandon, Vikram Patel, Bedirhan Ustun. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370: 851-8.
[3]
de Heer EW, Gerrits MM, Beekman AT, et al. The Association of Depression and Anxiety with Pain: A Study from NESDA. PLoS One 2014; 9(10): e106907.
[4]
Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001; 3(6): 244-54.
[5]
Chen J, Chen S, Landry PF. Urbanization and mental health in china: Linking the 2010 population census with a cross-sectional survey. Int J Environ Res Public Health 2015; 12(8): 9012-24.
[6]
Hakulinen C, Elovainio M, Pulkki-Raback L, et al. Personality and depressive symptoms: Individual participant meta-analysis of 10 cohort studies. Depress Anxiety 2015; 32(7): 461-70.
[7]
Taylor RJ, Chae DH, Lincoln KD, Chatters LM. Extended family and friendship support networks are both protective and risk factors for major depressive disorder and depressive symptoms among African-Americans and black Caribbeans. J Nerv Ment Dis 2015; 203(2): 132-40.
[8]
Hoven H, Wahrendorf M, Siegrist J. Occupational position, work stress and depressive symptoms: a pathway analysis of longitudinal SHARE data. J Epidemiol Community Health 2015; 69(5): 447-52.
[9]
World Bank Group/IMF Spring Meeting April 2016, Washington
D.C. http: //wwwworldbankorg/en/about.April
[10]
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Applications. 4th ed. Cambridge University Press: New York 2013.
[11]
Stahl SM. The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry 2001; 62(2): 80-1.
[12]
Rajkumar RP, Kumaran AK. Depression and anxiety in men with sexual dysfunction: a retrospective study. Compr Psychiatry 2015; 60: 114-8.
[13]
Jackson G. Prevention of cardiovascular disease by the early identification of erectile dysfunction. Int J Impot Res 2008; 20(Suppl. 2): S9-S14.
[14]
Basu J, Sharma S. Erectile dysfunction heralds onset of cardiovascular diseasePractitioner 2016; 260(1794): 21-3, 3
[15]
Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009; 84(2): 139-48.
[16]
Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? Eur Urol 2003; 44(3): 352-4.
[17]
Engel GL. The need for a new medical model: A challenge for biomedicine. Science 1977; 196(4286): 129-36.
[18]
Engel GL. The clinical application of the bio-psycho-social model. Am J Psychiatry 1980; 137(5): 535-44.
[19]
Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2): 47-52.
[20]
Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159(6): 2164-71.
[21]
Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79(6): 958-63.
[22]
Gresser U, Gleiter CH. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res 2002; 7(10): 435-46.
[24]
Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45(9): 987-1003.
[25]
Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53(Suppl. 1): 5S-12S.
[26]
Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56(6): 453-9.
[28]
Sajjad A, Weng CY. Vision Loss in a Patient with Primary Pulmonary
Hypertension and Long-Term Use of Sildenafil. Retinal cases
& brief reports 2016.
[29]
Yajima T, Yajima Y, Koppiker N, Grunwald JE, Laties AM. No clinically important effects on intraocular pressure after short-term administration of sildenafil citrate (Viagra). Am J Ophthalmol 2000; 129(5): 675-6.
[30]
Gur S, Yurdaarmagan B, Bayatli N, Sikka SC. Effect of short- and long-term sildenafil treatment on erectile dysfunction in rats with partial bladder outlet obstruction. Neurourol Urodyn 2016; 35(1): 108-14.
[31]
Seftel AD, Farber J, Fletcher J, et al. A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia. Int J Impot Res 2005; 17(5): 455-61.
[32]
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P&T 2013; 38(7): 407-19.
[33]
Rodriguez JJ, Al Dashti R, Schwarz ER. Linking erectile dysfunction and coronary artery disease. Int J Impot Res 2005; 17(Suppl. 1): S12-8.
[34]
Andrews NP, Husain M, Dakak N, Quyyumi AA. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001; 37(2): 510-6.
[35]
Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32(Suppl. 2): S314-21.
[36]
Shabsigh R, Stone B. Understanding the needs and objectives of erectile dysfunction patients. World J Urol 2006; 24(6): 618-22.
[37]
Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the massachusetts male aging study. Psychosom Med 1998; 60(4): 458-65.
[38]
Jeong JY, Lee SK, Kang YW, Jang SN, Choi YJ, Kim DH. Relationship between ED and depression among middle-aged and elderly men in Korea: Hallym aging study. Int J Impot Res 2011; 23(5): 227-34.
[39]
Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 2002; 4(1): 7-20.
[40]
Schechter LE, Ring RH, Beyer CE, et al. Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRx 2005; 2(4): 590-611.
[41]
Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: Influences on male sexual behavior. Physiol Behav 2004; 83(2): 291-307.
[42]
Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. CMAJ 1998; 159(10): 1245-52.
[43]
Gartlehner G, Hansen RA, Reichenpfader U, et al. Drug class review: second-generation antidepressants: Final update 5 report. Drug Class Reviews: Portland, OR 2011.
[44]
De Long NE, Stepita RA, Taylor VH, Holloway AC. Major depressive disorder and diabetes: Does serotonin bridge the gap? Curr Diabetes Rev 2015; 11(2): 71-8.
[45]
Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009; 5: 563-76.
[46]
Manikandan S. Agomelatine: A novel melatonergic antidepressant. J Pharmacol Pharmacother 2010; 1(2): 122-3.
[47]
Sansone RA, Sansone LA. Agomelatine: A novel antidepressant. Innov Clin Neurosci 2011; 8(11): 10-4.
[48]
Howland RH. Agomelatine: a novel atypical antidepressant. J Psychosoc Nurs Ment Health Serv 2007; 45(12): 13-7.
[49]
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6(4): 159-66.
[50]
Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67(Suppl. 6): 3-8.
[51]
Grunebaum MF, Keilp JG, Ellis SP, et al. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial. J Clin Psychiatry 2013; 74(9): 872-9.
[52]
Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual dysfunction due to psychotropic medications. Psychiatr Clin North Am 2016; 39(3): 427-63.
[53]
de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10(Suppl. 4): 19-23.
[54]
Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011; (12): CD006528.
[55]
Simopoulos EF, Trinidad AC. Male erectile dysfunction: Integrating psychopharmacology and psychotherapy. Gen Hosp Psychiatry 2013; 35(1): 33-8.
[56]
Viera AJ, Clenney TL, Shenenberger DW, Green GF. Newer pharmacologic alternatives for erectile dysfunction. Am Fam Physician 1999; 60(4) 1159-66, 69, 72.
[57]
Barada JH. Optimizing outcomes of oral therapy for patients with erectile dysfunction. Rev Urol 2003; 5(Suppl. 7): S28-34.
[58]
Taylor MJ, Rudkin L, Bullemor‐Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; (5): CD003382.
Article Metrics
37
3